‘‘(b) EXPANSION OF GESTATIONAL DIABETES RE-
SEARCH.— 
‘‘(1) IN GENERAL.—The Secretary shall expand 
and intensify public health research regarding gesta-
tional diabetes. Such research may include— 
‘‘(A) developing and testing novel ap-
proaches for improving postpartum diabetes 
testing or screening and for preventing type 2 
diabetes in women with a history of gestational 
diabetes; and 
‘‘(B) conducting public health research to 
further understanding of the epidemiologic, 
socioenvironmental, behavioral, translation, and 
biomedical factors and health systems that in-
fluence the risk of gestational diabetes and the 
development of type 2 diabetes in women with 
a history of gestational diabetes. 
‘‘(2) AUTHORIZATION
OF
APPROPRIATIONS.— 
There is authorized to be appropriated to carry out 
this subsection $5,000,000 for each of fiscal years 
2012 through 2016. 
‘‘(c) DEMONSTRATION GRANTS TO LOWER
THE 
RATE OF GESTATIONAL DIABETES.— 
‘‘(1) IN
GENERAL.—The Secretary, acting 
through the Director of the Centers for Disease 
VerDate Mar 15 2010 
01:25 Jun 18, 2011
Jkt 099200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H2194.IH
H2194
pwalker on DSK5TPTVN1PROD with BILLS
Control and Prevention, shall award grants, on a 
competitive basis, to eligible entities for demonstra-
tion projects that implement evidence-based inter-
ventions to reduce the incidence of gestational diabe-
tes, the recurrence of gestational diabetes in subse-
quent pregnancies, and the development of type 2 di-
abetes in women with a history of gestational diabe-
tes. 
‘‘(2) PRIORITY.—In making grants under this 
subsection, the Secretary shall give priority to 
projects focusing on— 
‘‘(A) helping women who have 1 or more 
risk factors for developing gestational diabetes; 
‘‘(B) working with women with a history of 
gestational diabetes during a previous preg-
nancy; 
‘‘(C) providing postpartum care for women 
with gestational diabetes; 
‘‘(D) tracking cases where women with a 
history of gestational diabetes developed type 2 
diabetes; 
‘‘(E) educating mothers with a history of 
gestational diabetes about the increased risk of 
their child developing diabetes; 
VerDate Mar 15 2010 
01:25 Jun 18, 2011
Jkt 099200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H2194.IH
H2194
pwalker on DSK5TPTVN1PROD with BILLS
‘‘(F) working to prevent gestational diabe-
tes and prevent or delay the development of 
type 2 diabetes in women with a history of ges-
tational diabetes; and 
‘‘(G) achieving outcomes designed to assess 
the efficacy and cost-effectiveness of interven-
tions that can inform decisions on long-term 
sustainability, including third-party reimburse-
ment. 
‘‘(3) APPLICATION.—An eligible entity desiring 
to receive a grant under this subsection shall submit 
to the Secretary— 
‘‘(A) an application at such time, in such 
manner, and containing such information as the 
Secretary may require; and 
‘‘(B) a plan to— 
‘‘(i) lower the rate of gestational dia-
betes during pregnancy; or 
‘‘(ii) develop methods of tracking 
women with a history of gestational diabe-
tes and develop effective interventions to 
lower the incidence of the recurrence of 
gestational diabetes in subsequent preg-
nancies and the development of type 2 dia-
betes. 
VerDate Mar 15 2010 
01:25 Jun 18, 2011
Jkt 099200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H2194.IH
H2194
pwalker on DSK5TPTVN1PROD with BILLS
‘‘(4) USES OF FUNDS.—An eligible entity re-
ceiving a grant under this subsection shall use the 
grant funds to carry out demonstration projects de-
scribed in paragraph (1), including— 
‘‘(A) expanding community-based health 
promotion education, activities, and incentives 
focused on the prevention of gestational diabe-
tes and development of type 2 diabetes in 
women with a history of gestational diabetes; 
‘‘(B) aiding State- and tribal-based diabe-
tes prevention and control programs to collect, 
analyze, disseminate, and report surveillance 
data on women with, and at risk for, gesta-
tional diabetes, the recurrence of gestational di-
abetes in subsequent pregnancies, and, for 
women with a history of gestational diabetes, 
the development of type 2 diabetes; and 
‘‘(C) training and encouraging health care 
providers— 
‘‘(i) to promote risk assessment, high- 
quality care, and self-management for ges-
tational diabetes and the recurrence of ges-
tational diabetes in subsequent preg-
nancies; and 
VerDate Mar 15 2010 
01:25 Jun 18, 2011
Jkt 099200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H2194.IH
H2194
pwalker on DSK5TPTVN1PROD with BILLS
‘‘(ii) to prevent the development of 
type 2 diabetes in women with a history of 
gestational diabetes, and its complications 
in the practice settings of the health care 
providers. 
‘‘(5) REPORT.—Not later than 4 years after the 
date of the enactment of this section, the Secretary 
shall prepare and submit to the Congress a report 
concerning the results of the demonstration projects 
conducted through the grants awarded under this 
subsection. 
‘‘(6) DEFINITION
OF
ELIGIBLE
ENTITY.—In 
this subsection, the term ‘eligible entity’ means a 
nonprofit organization (such as a nonprofit academic 
center or community health center) or a State, trib-
al, or local health agency. 
‘‘(7) AUTHORIZATION
OF
APPROPRIATIONS.— 
There is authorized to be appropriated to carry out 
this subsection $5,000,000 for each of fiscal years 
2012 through 2016. 
‘‘(d) POSTPARTUM FOLLOW-UP REGARDING GESTA-
TIONAL DIABETES.—The Secretary, acting through the 
Director of the Centers for Disease Control and Preven-
tion, shall work with the State- and tribal-based diabetes 
prevention and control programs assisted by the Centers 
VerDate Mar 15 2010 
01:25 Jun 18, 2011
Jkt 099200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H2194.IH
H2194
pwalker on DSK5TPTVN1PROD with BILLS
to encourage postpartum follow-up after gestational diabe-
tes, as medically appropriate, for the purpose of reducing 
the incidence of gestational diabetes, the recurrence of 
gestational diabetes in subsequent pregnancies, the devel-
opment of type 2 diabetes in women with a history of ges-
tational diabetes, and related complications.’’. 
Æ 
VerDate Mar 15 2010 
01:25 Jun 18, 2011
Jkt 099200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6301
E:\BILLS\H2194.IH
H2194
pwalker on DSK5TPTVN1PROD with BILLS